RESUMO
The management of melanoma significantly improved within the last 25 years. Chemotherapy was the first approved systemic therapeutic approach and resulted in a median overall of survival less than 1 year, without survival improvement in phase III trials. High-dose interferon α2b and IL-2 were introduced for resectable high-risk and advanced disease, respectively, resulting in improved survival and response rates. The anti-CTLA4 and anti-programmed death 1 monoclonal antibodies along with BRAF/MEK targeted therapies are the dominant therapeutic classes of agent for melanoma. This article provides an historic overview of the evolution of melanoma management.
Assuntos
Antineoplásicos , Melanoma , Neoplasias Cutâneas , Antineoplásicos/história , Antineoplásicos/imunologia , Antineoplásicos/uso terapêutico , Vacinas Anticâncer/história , Vacinas Anticâncer/uso terapêutico , História do Século XVIII , História do Século XIX , História do Século XX , História do Século XXI , Humanos , Imunoterapia/história , Imunoterapia/métodos , Metástase Linfática , Melanoma/história , Melanoma/fisiopatologia , Melanoma/terapia , Terapia de Alvo Molecular/história , Terapia de Alvo Molecular/métodos , Estadiamento de Neoplasias , Biópsia de Linfonodo Sentinela , Neoplasias Cutâneas/história , Neoplasias Cutâneas/fisiopatologia , Neoplasias Cutâneas/terapiaAssuntos
Pesquisa Biomédica/história , Vacinas Anticâncer/história , Criança , Saúde da Criança , Obtenção de Fundos/história , História do Século XX , Humanos , Leucemia/tratamento farmacológico , Leucemia/história , Leucemia/virologia , Oncologia , Vacinas contra Poliovirus/história , Estados Unidos , VirologiaRESUMO
In September 2018, Professor Volodymyr Oleksiiovych Shlyakhovenko, well-known Ukrainian scientist in the field of cancer biochemistry, celebrated his 80th anniversary.
Assuntos
Bioquímica/história , Neoplasias/história , Vacinas Anticâncer/biossíntese , Vacinas Anticâncer/história , Ceruloplasmina/análise , Ceruloplasmina/história , Eletroforese em Gel de Ágar/história , Eletroforese em Gel de Ágar/instrumentação , Eletroforese em Gel de Poliacrilamida/história , Eletroforese em Gel de Poliacrilamida/instrumentação , História do Século XX , História do Século XXI , Humanos , Masculino , Neoplasias/enzimologia , UcrâniaAssuntos
Vacinas contra Papillomavirus/história , Vacinas Anticâncer/história , Epigenômica/história , Feminino , História do Século XX , História do Século XXI , Humanos , Reino Unido , Neoplasias do Colo do Útero/genética , Neoplasias do Colo do Útero/história , Neoplasias do Colo do Útero/prevenção & controleRESUMO
After the end of the Second World War, cancer virus research experienced a remarkable revival, culminating in the creation in 1964 of the United States National Cancer Institute's Special Virus Leukemia Program (SVLP), an ambitious program of directed biomedical research to accelerate the development of a leukemia vaccine. Studies of cancer viruses soon became the second most highly funded area of research at the Institute, and by far the most generously funded area of biological research. Remarkably, this vast infrastructure for cancer vaccine production came into being before a human leukemia virus was shown to exist. The origins of the SVLP were rooted in as much as shifts in American society as laboratory science. The revival of cancer virus studies was a function of the success advocates and administrators achieved in associating cancer viruses with campaigns against childhood diseases such as polio and leukemia. To address the urgency borne of this new association, the SVLP's architects sought to lessen the power of peer review in favor of centralized Cold War management methods, fashioning viruses as "administrative objects" in order to accelerate the tempo of biomedical research and discovery.
Assuntos
Academias e Institutos/história , Pesquisa Biomédica/história , Vacinas Anticâncer/história , Leucemia/história , Ciência/história , Virologia/história , Criança , Financiamento da Assistência à Saúde , História do Século XX , Humanos , Leucemia/virologia , Revisão por Pares , Estados UnidosAssuntos
Vacinas Bacterianas/imunologia , Vacinas Anticâncer/imunologia , Neoplasias/imunologia , Neoplasias/terapia , Vacinas Bacterianas/história , Vacinas Bacterianas/microbiologia , Vacinas Bacterianas/uso terapêutico , Vacinas Anticâncer/história , Vacinas Anticâncer/uso terapêutico , História do Século XIX , História do Século XX , História do Século XXI , Humanos , Fatores Imunológicos/imunologia , Imunoterapia/história , Imunoterapia/métodos , Imunoterapia/tendências , Neoplasias/microbiologia , Sarcoma/imunologia , Sarcoma/microbiologia , Sarcoma/terapia , Serratia marcescens/imunologia , Streptococcus pyogenes/imunologiaAssuntos
Pesquisa Biomédica/história , Neoplasias/história , Antineoplásicos/história , Antineoplásicos/uso terapêutico , Neoplasias da Mama/história , Neoplasias da Mama/cirurgia , Vacinas Anticâncer/história , História do Século XIX , História do Século XX , História do Século XXI , Humanos , Imunoterapia/história , Neoplasias/etiologia , Neoplasias/mortalidade , Neoplasias/terapia , Radioterapia/história , Taxa de SobrevidaAssuntos
Imunidade Adaptativa/imunologia , Alergia e Imunologia/história , Células Dendríticas/imunologia , Prêmio Nobel , Canadá , Vacinas Anticâncer/história , Vacinas Anticâncer/imunologia , História do Século XX , História do Século XXI , Humanos , Neoplasias/imunologia , Neoplasias/terapia , Estados UnidosRESUMO
Our current understanding of tumourigenesis suggests that cancer develops as a series of cumulative genetic and epigenetic derangements across time culminating in a clone of cells differing from its population of origin in terms of cellular identity, growth control, and its contextual relationship to its environment. Our increasing knowledge of the timing, sequence, frequency, and specific implications of these changes provides unique opportunities for earlier identification of aberrations and preventive interventions. Here we discuss the fundamentals of cancer prevention including the targets, cohorts, agents, endpoints, mechanistic biomarkers, designs, and strategies employed in preventive drug development. There have been many notable successes in this field such as the identification and development of tamoxifen and raloxifene for breast cancer risk reduction, instillational BCG and valrubicin for treatment of preinvasive bladder cancer, and a variety of topical and systemic agents that effectively treat preinvasive neoplastic lesions of the skin. A variety of null or negative developmental endeavours have occurred as well, including trials of beta-carotene for lung cancer prevention, nutritional modifications for colorectal adenoma prevention, and most recently, selenium and alpha-tocopherol for prostate cancer prevention. A third category of prevention trials can be summarized as investigationally successful, but not achieving regulatory success. The development of finasteride and dutasteride for prostate cancer prevention, and celecoxib for colorectal neoplasia prevention fall into this category. In less than four decades, cancer chemoprevention has transformed from a concept to an achievable reality.
Assuntos
Anticarcinógenos/uso terapêutico , Vacinas Anticâncer/uso terapêutico , Neoplasias/prevenção & controle , Animais , Anticarcinógenos/história , Vacinas Anticâncer/história , Quimioprevenção/história , História do Século XX , História do Século XXI , Humanos , Neoplasias/genética , Neoplasias/história , Neoplasias/patologiaAssuntos
Alergia e Imunologia/história , Vacinas Anticâncer/imunologia , Células Dendríticas/imunologia , Medicina de Precisão , Idoso , Alergia e Imunologia/tendências , Vacinas Anticâncer/história , Vacinas Anticâncer/uso terapêutico , História do Século XX , História do Século XXI , Humanos , Masculino , Prêmio Nobel , Neoplasias Pancreáticas/imunologia , Neoplasias Pancreáticas/terapia , Medicina de Precisão/história , Medicina de Precisão/tendênciasRESUMO
Vaccination, the revolutionary prophylactic immunotherapy developed in the eighteenth century, has become the most successful and cost-effective of medical remedies available to modern society. Due to the remarkable accomplishments of the past century, the number of diseases and pathogens for which a traditional vaccine approach might reasonably be employed has dwindled to unprecedented levels. While this happy scenario bodes well for the future of public health, modern immunologists and vaccinologists face significant challenges if we are to address the scourge of recalcitrant pathogens like HIV and HCV and well as the significant obstacles to immunotherapy imposed by neoplastic self. Here, the authors review the clinical and preclinical literature to highlight the manner by which the host immune system can be successfully manipulated by cytokine adjuvants, thereby significantly enhancing the efficacy of a wide variety of vaccination platforms.
Assuntos
Vacinas contra a AIDS/uso terapêutico , Adjuvantes Imunológicos/uso terapêutico , Vacinas Anticâncer/uso terapêutico , Citocinas/uso terapêutico , Vacinação/métodos , Vacinas contra Hepatite Viral/uso terapêutico , Vacinas contra a AIDS/história , Vacinas contra a AIDS/imunologia , Adjuvantes Imunológicos/história , Animais , Vacinas Anticâncer/história , Vacinas Anticâncer/imunologia , Citocinas/história , Citocinas/imunologia , História do Século XVIII , História do Século XIX , História do Século XX , História do Século XXI , Humanos , Vacinação/história , Vacinas contra Hepatite Viral/história , Vacinas contra Hepatite Viral/imunologiaRESUMO
INTRODUCTION: Although considerable evidence supports the hypothesis that T cells play a critical role in the immune response against cancer, the ability to mount and sustain tumor-specific cellular responses in vivo remains a challenge. A strategy that harnesses the cytotoxic advantage of T cell therapy is the use of bispecific antibodies designed to engage and activate endogenous polyclonal T cell populations via the CD3 complex, but only in the presence of a tumor antigen. While antibody constructs with dual specificity were first described as anticancer therapeutics over 25 years ago, it was not until recently that one subclass of bispecific single-chain antibody, the bispecific T cell engager (BiTE), emerged as superior to previous iterations in achieving efficacy in animal models and early clinical trials. AREAS COVERED: The evolution of bispecific antibodies in antitumor immunotherapy is reviewed and the greatest hurdles impeding their clinical translation are discussed, specifically in the context of immunoprivileged sites as is the case for intracerebral malignancy. EXPERT OPINION: The BiTE platform has great potential in the treatment of malignant disease. Despite burgeoning interest in bispecific antibodies and permutations thereof, the issues of stability and cost-effective production persist as obstacles.
Assuntos
Anticorpos Biespecíficos/farmacologia , Vacinas Anticâncer/farmacologia , Ativação Linfocitária/efeitos dos fármacos , Neoplasias/tratamento farmacológico , Linfócitos T/efeitos dos fármacos , Evasão Tumoral/efeitos dos fármacos , Animais , Anticorpos Biespecíficos/história , Antígenos de Neoplasias/imunologia , Complexo CD3/imunologia , Vacinas Anticâncer/história , História do Século XX , História do Século XXI , Humanos , Neoplasias/imunologia , Linfócitos T/imunologiaRESUMO
Almost 100 years have passed since the seminal observations of Schöne showing that vaccination of animals with fetal tissue would prevent the growth of transplantable tumors. Many subsequent reports have affirmed the general idea that immunologic rejection of transplantable tumors, as well as prevention of carcinogenesis, may be affected by vaccination with embryonic/fetal material. Following a decade of intense research on this phenomenon during approximately 1964-1974, interest appears to have waned. This earlier experimental work may be particularly pertinent in view of the rising interest in so-called cancer stem cells. We believe that further work - perhaps involving the use of embryonic stem cells as immunogens - is warranted and that the results reviewed herein support the concept that vaccination against the appearance of cancers of all kinds is a real possibility.
Assuntos
Vacinas Anticâncer , Animais , Antígenos de Neoplasias , Vacinas Anticâncer/história , Células-Tronco Embrionárias/imunologia , Feminino , História do Século XIX , História do Século XX , História do Século XXI , Humanos , Neoplasias/imunologia , Neoplasias/terapia , Gravidez/imunologiaRESUMO
Standard systemic treatment of prostate cancer today is comprised of antihormonal and cytostatic agents. Vaccine therapy of prostate cancer is principally attractive because of the presence of tumor-associated antigens such as prostate-specific antigen (PSA), prostatic acid phosphatase (PAP), prostate-specific membrane antigen (PSMA), and others. Most prostate cancer vaccine trials have demonstrated some activation of the immune system, limited clinical success, and few adverse effects.One strategy to overcome the problem of limited clinical success of vaccine therapies in prostate cancer could be strict patient selection. The clinical course of patients with prostate cancer (even in those with PSA relapse following surgery or radiotherapy with curative intention, or those with metastatic disease) can vary significantly. In patients with organ-confined prostate cancer, the most promising immunotherapeutic approach would be an adjuvant therapy following surgery or radiotherapy. Patients with PSA relapse following surgery or radiotherapy could also benefit from immunotherapy because tumor burden is usually low. However, most patients in prostate cancer vaccine trials had metastatic hormone-refractory prostate cancer (HRPC). High tumor burden correlates with immune escape phenomena. Nevertheless, 2 years ago, it was demonstrated, for the first time, that a tumor vaccine can prolong survival compared with placebo in patients with HRPC. This was demonstrated with the vaccine sipuleucel-T (APC-8015; Provenge), a mixture of cells obtained from the patient's peripheral blood by leukapheresis followed by density centrifugation and exposition. The Biologics License Application for this vaccine was denied by the US FDA in mid 2007, however, because the trial had failed to reach the primary endpoint (prolongation of time to tumor progression). Nevertheless, clinical trials with sipuleucel-T are ongoing, and the approach still looks promising. Another interesting approach is a vaccine made from whole tumor cells: GVAX. This vaccine is presently being studied in phase III trials against, and in combination with, docetaxel. The results from these trials will become available in the near future. Besides the precise definition of the disease status of patients with prostate cancer, combinations of vaccine therapy with radiotherapy, chemotherapy, and/or hormonal therapy are approaches that look promising and deserve further investigation.
Assuntos
Vacinas Anticâncer/uso terapêutico , Terapia Genética/métodos , Imunoterapia Adotiva/métodos , Neoplasias da Próstata/tratamento farmacológico , Animais , Vacinas Anticâncer/história , Vacinas Anticâncer/imunologia , Citocinas/genética , Citocinas/metabolismo , Células Dendríticas/imunologia , Células Dendríticas/transplante , História do Século XX , História do Século XXI , Humanos , Masculino , Antígeno Prostático Específico/genética , Antígeno Prostático Específico/imunologia , Neoplasias da Próstata/genética , Neoplasias da Próstata/imunologia , RNA Neoplásico/metabolismo , Extratos de Tecidos/uso terapêutico , Transfecção , Resultado do Tratamento , Evasão Tumoral , Vacinas de DNA/uso terapêutico , Vacinas de Subunidades AntigênicasRESUMO
The individual, unique tumor Ags, which characterize each single tumor, were described 50 years ago in rodents but their molecular characterization was limited to few of them and obtained during the last 20 years. Here we summarize the evidence for the existence and the biological role of such Ags in human tumors, although such evidence was provided only during the last 10 years and by a limited number of studies, a fact leading to a misrepresentation of unique Ags in human tumor immunology. This was also due to the increasing knowledge on the shared, self-human tumor Ags, which have been extensively used as cancer vaccines. In this review, we highlight the biological and clinical importance of unique Ags and suggest how they could be used in clinical studies aimed at assessing their immunogenic and clinical potential both in active and adoptive immunotherapy of human tumors.